# NRXP earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/NRXP) · [Earnings tab](https://www.lopjlb.com/stock/NRXP?tab=earnings)

Updated: 2026-11-14T06:28:56

Quarters analyzed: 8

## Cross-quarter narrative

Across eight quarters, NRx Pharmaceuticals shifted from pre-revenue NDA preparation to early commercial inflection. In late 2024, management targeted 2024 NDA filings for NRX-100 (preservative-free IV ketamine) and NRX-101 (D-cycloserine/lurasidone), launched the Hope Therapeutics clinic subsidiary with a $25M revenue goal, and retired toxic debt. By mid-2025, the company reported its first clinic revenue, cut operating losses ~50% YoY, and secured a $6.5M raise extending cash into Q2 2026. The 2025 Q3 call added granularity: KETAFREE NDA/ANDA on track, NRX-100 accelerated approval at risk, NRX-101 Phase 3 initiated, ONE-D protocol delivered, and expanded access underway. Reimbursement per session (<$500) was flagged as a margin constraint, with future protocols expected to improve economics. Regulatory uncertainty around CNPV and citizen petitions, manufacturing reliance on Blow-Fill-Seal, and clinic acquisition integration risk were explicitly cited. In 2026 Q2, multiple catalysts converged: KETAFREE ANDA nearing approval with a single deficiency resolved, NRX-100 NDA guided by executive order/congressional language, NRX-101 SPARC-TMS trial expanding from military to broad TRD with DARPA support, and the GeNeuro acquisition adding ALS/schizophrenia assets backed by federal funding. The narrative arc moves from pipeline promise and clinic rollout to tangible regulatory progress, revenue initiation, and strategic expansion into new indications with government partnerships. Cash runway visibility improved but remains tied to milestone execution. Management tone moderated from 0.8 to 0.6 with rising QA pressure (0.4) and uncertainty (0.6) as binary regulatory events approach. The company now sits at a multi-program inflection with clinic revenue, three advancing drug pathways, and an expanded asset base. The core themes — regulatory de-risking, clinic network monetization, manufacturing scale-up, and reimbursement improvement — are all in motion but not yet resolved. 

## Latest CallCard · Q2

NRx reports Q2 2026 inflection: KETAFREE ANDA nearing approval with single deficiency resolved, NRX-100 NDA guided by executive order/congressional language, NRX-101 SPARC-TMS trial with DARPA/military expands to broad TRD, GeNeuro acquisition adds ALS/schizophrenia assets with federal funding, cash

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2026 Q2:** NRx reports Q2 2026 inflection: KETAFREE ANDA nearing approval with single deficiency resolved, NRX-100 NDA guided by executive order/congressional language, NRX-101 SPARC-TMS trial with DARPA/military expands to broad TRD, GeNeuro acquisition adds ALS/schizophrenia assets with federal funding, cash
- **2026 Q1:** —
- **2025 Q4:** —
- **2025 Q3:** NRx reported its first clinic revenue, progress on KETAFREE, NRX-100 and NRX-101 filings, expanded access and acquisition plans, while noting cash will fund operations through Q2 2026 but regulatory and execution milestones remain pending.
- **2025 Q2:** NRx advances three drug approval pathways (NRX-100 NDA/ANDA, NRX-101 breakthrough) and Hope Therapeutics clinic acquisitions; operating loss cut ~50% YoY; $6.5M raise extends cash runway into 2026.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management highlights vital advances across programs, expand
- **2025 Q1:** —
- **2024 Q4:** NRx CEO Javitt outlines path to revenue by end-2025 via NDA filings for NRX-100 (preservative-free IV ketamine) and NRX-101 (D-cycloserine/lurasidone), HOPE clinic acquisitions, and a potential $300M+ licensing deal, after raising capital and retiring toxic debt.','tone':{'mgmt':0.8,'mgmt_rationale'
- **2024 Q3:** NRx Pharmaceuticals advances NRX-100 and NRX-101 NDAs for 2024 filing, launches Hope Therapeutics subsidiary targeting $25M revenue by year-end via precision psychiatry clinic acquisitions, reports 74% loss reduction, forecasts 2025 profitability.','tone': {'mgmt': 0.8, 'mgmt_rationale': 'Management

## Guidance path

2024 Q3:vague → 2024 Q4:vague → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:maintained → 2025 Q4:vague → 2026 Q1:vague → 2026 Q2:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/NRXP`